Sign In
Buy ALDX
$1.86
+0.220 (+13.41%)
At Close: Jun 03, 2026
Aldeyra Therapeutics Inc (ALDX): Hedge Funds In Wait-and-See Mode
01:28am, Wednesday, 08'th Jul 2020
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin
Aldeyra Therapeutics (ALDX) Gets a Buy Rating from Oppenheimer - Markets
07:16pm, Tuesday, 07'th Jul 2020
Oppenheimer analyst Justin Kim assigned a Buy rating to Aldeyra Therapeutics (ALDX – Research Report) today and set a price
Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease
12:00pm, Tuesday, 07'th Jul 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun
JPMorgan Chase & Co. Boosts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)
04:06am, Sunday, 05'th Jul 2020
JPMorgan Chase & Co. boosted its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 756.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and
What Kind Of Investors Own Most Of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)?
03:15pm, Friday, 03'rd Jul 2020
Every investor in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) should be aware of the most powerful shareholder groups...
What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Strong Buy Stock
04:00pm, Monday, 22'nd Jun 2020
Aldeyra Therapeutics, Inc. (ALDX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near te
Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study
02:12pm, Thursday, 18'th Jun 2020
Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.
Oppenheimer Releases a Buy Rating on Provention Bio (PRVB) - Markets
08:13pm, Monday, 15'th Jun 2020
Oppenheimer analyst Justin Kim assigned a Buy rating to Provention Bio (PRVB – Research Report) today and set a price
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment. AD
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that ADX-2191 has been designated an orphan medicinal product by the European Comm
Connor Clark & Lunn Investment Management Ltd. Grows Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)
07:34am, Sunday, 14'th Jun 2020
Connor Clark & Lunn Investment Management Ltd. boosted its stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 11.4% in the first quarter, according to the company in its most recent disclosure with t
FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher
12:37am, Thursday, 11'th Jun 2020
FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Edited Transcript of ALDX earnings conference call or presentation 7-May-20 12:00pm GMT
10:28pm, Sunday, 07'th Jun 2020
Q1 2020 Aldeyra Therapeutics Inc Earnings Call
Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:ALDX)
06:01am, Sunday, 07'th Jun 2020
Aldeyra progresses with Reproxalap in dry eye disease. Kezar reports strong data for SLE drug candidate. AbbVie posts positive data for RINVOQ.
